5α-dihydrotestosterone inhibits Iα,25-dihydroxyvitamin D3-induced expression of CYP24 in human prostate cancer cells

被引:14
作者
Lou, YR [1 ]
Nazarova, N
Talonpoika, R
Tuohimaa, P
机构
[1] Tampere Univ, Dept Anat, Sch Med, FIN-33014 Tampere, Finland
[2] Tampere Univ Hosp, Dept Clin Chem, FIN-33521 Tampere, Finland
关键词
25-hydroxyvitamin D-3 24-hydroxylase; I alpha; 25-dihydroxyvitamin D-3; androgen receptor; DHT; LNCaP; prostate cancer;
D O I
10.1002/pros.20189
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
BACKGROUND. A cross-talk between la,25-dihydroxyvitamin D-3 [1 alpha.,25-(OH)(2)D-3] and 5 alpha-dihydrotestosterone (DHT) in the growth inhibition has been demonstrated, but the mechanism is unknown. METHODS. The expression of 25-hydroxyvitamin D-3 24-hydroxylase (24-hydroxylase) was measured using a real-time quantitative RT-PCR assay and the catabolism of 1 alpha,25-(OH)(2)D-3 was measured using a radioreceptor assay. RESULTS. Real-time RT-PCR showed that DHT at 1-100 nM significantly inhibited 1 alpha,25-(OH)(2)D-3-induced expression of 24-hydroxylase in LNCaP cells. Furthermore, the catabolism of 1 alpha,25-(OH)(2)D-3 was decreased by 10 nM DHT. An androgen receptor (AR) antagonist, Casodex antagonized the DHT effect, whereas an AR agonist (due to the mutant AR in LNCaP cells) hydroxyflutamide did not. CONCLUSIONS. We demonstrated, for the first time, that DHT reduces the ability of 1 alpha,25-(OH)(2)D-3 to induce 24-hydroxylase expression. Our results not only support the earlier finding of a cross-talk between androgen and vitamin D in human prostate cancer cells but also provide a possible mechanism how androgen and vitamin D signaling pathways may interact. (c) 2004 Wiley-Liss. Inc.
引用
收藏
页码:222 / 230
页数:9
相关论文
共 44 条
[31]   A MICRO-ASSAY FOR 1,25-DIHYDROXYVITAMIN-D NOT REQUIRING HIGH-PERFORMANCE LIQUID-CHROMATOGRAPHY - APPLICATION TO CLINICAL-STUDIES [J].
REINHARDT, TA ;
HORST, RL ;
ORF, JW ;
HOLLIS, BW .
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 1984, 58 (01) :91-98
[32]  
SCHWARTZ GG, 1994, ANTICANCER RES, V14, P1077
[33]   Incorporation of gamma-galactosidase-expressing endothelial cells into the skeletal muscle microvascular bed of mice [J].
Schwarzler, C ;
Webersinke, G ;
Fassler, R ;
Lametschwandtner, A ;
Bauer, H ;
Bauer, HC .
CELL TRANSPLANTATION, 1997, 6 (01) :9-15
[34]   VITAMIN-D AND PROSTATE-CANCER - 1,25-DIHYDROXYVITAMIN-D3 RECEPTORS AND ACTIONS IN HUMAN PROSTATE-CANCER CELL-LINES [J].
SKOWRONSKI, RJ ;
PEEHL, DM ;
FELDMAN, D .
ENDOCRINOLOGY, 1993, 132 (05) :1952-1960
[35]   Photoperiod-induced changes in androgen receptor expression in testes and accessory sex glands of the bank vole, Clethrionomys glareolus [J].
Tahka, KM ;
Zhuang, YH ;
Tahka, S ;
Tuohimaa, P .
BIOLOGY OF REPRODUCTION, 1997, 56 (04) :898-908
[36]   A RAPID AND SIMPLE METHOD FOR THE MEASUREMENT OF PLASMA 25-HYDROXYVITAMIN-D2 AND 25-HYDROXYVITAMIN-D3 USING SEP-PAK C-18 CARTRIDGES AND A SINGLE HIGH-PERFORMANCE LIQUID-CHROMATOGRAPHIC STEP [J].
TURNBULL, H ;
TRAFFORD, DJH ;
MAKIN, HLJ .
CLINICA CHIMICA ACTA, 1982, 120 (01) :65-76
[37]   THE ANDROGEN RECEPTOR IN LNCAP CELLS CONTAINS A MUTATION IN THE LIGAND-BINDING DOMAIN WHICH AFFECTS STEROID BINDING CHARACTERISTICS AND RESPONSE TO ANTIANDROGENS [J].
VELDSCHOLTE, J ;
BERREVOETS, CA ;
RISSTALPERS, C ;
KUIPER, GGJM ;
JENSTER, G ;
TRAPMAN, J ;
BRINKMANN, AO ;
MULDER, E .
JOURNAL OF STEROID BIOCHEMISTRY AND MOLECULAR BIOLOGY, 1992, 41 (3-8) :665-669
[38]  
WIESE RJ, 1992, J BIOL CHEM, V267, P20082
[39]   Androgen inhibition of MAP kinase pathway and Elk-1 activation in proliferating osteloblasts [J].
Wiren, KM ;
Toombs, AR ;
Zhang, XW .
JOURNAL OF MOLECULAR ENDOCRINOLOGY, 2004, 32 (01) :209-226
[40]   1α,25-dihydroxyvitamin D3 inhibits prostate cancer cell growth by androgen-dependent and androgen-independent mechanisms [J].
Zhao, XY ;
Peehl, DM ;
Navone, NM ;
Feldman, D .
ENDOCRINOLOGY, 2000, 141 (07) :2548-2556